Navigation Links
Ventana to collaborate with Boehringer Ingelheim on the development of companion diagnostic tests
Date:9/19/2013

TUCSON, Ariz. and INGELHEIM, Germany, Sept. 19, 2013 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, and Boehringer Ingelheim (BI) announced today that they have entered into an agreement to collaborate on the development of companion diagnostic tests for Boehringer Ingelheim oncology programs.

(Photo: http://photos.prnewswire.com/prnh/20130919/LA82369)

As part of the agreement, Ventana will utilize its immunohistochemistry technology platform, experience and expertise in companion diagnostic development and premarket approval (PMA) submissions to support Boehringer Ingelheim's personalized medicine healthcare strategies for cancer drug development.

Companion diagnostic tests provide information that aids physicians in choosing targeted treatments for their patients based on the expected best response to therapy. By integrating the development of companion diagnostic kits and drug candidates, Boehringer Ingelheim strives to yield cancer treatments with optimized benefit risk profiles.

"We are pleased that our commitment to enable Personalized Healthcare for patients worldwide was recognized by Boehringer Ingelheim when they selected Ventana to be a companion diagnostics development partner for their oncology programs," says Mara G. Aspinall, President, Ventana Medical Systems, Inc.

"We look forward to partnering with Ventana and accessing their significant capabilities and expertise in developing companion diagnostics that will complement our products to further advance the delivery of personalized healthcare solutions for patients," says Klaus Dugi, Corporate Senior Vice President, Medicine at Boehringer Ingelheim.

In addition to Boehringer Ingelheim, Ventana has worked with more than 45 biopharmaceutical partners over the past decade and is currently engaged in over 150 collaborative projects to develop and commercialize companion diagnostics globally.

About Ventana Medical Systems, Inc.

Ventana Medical Systems, Inc. ("VMSI") (SIX: RO, ROG; OTCQX: RHHBY), a member of the Roche Group, innovates and manufactures instruments and reagents that automate tissue processing and slide staining for cancer diagnostics. VENTANA solutions are used in clinical histology and drug development research laboratories worldwide. The company's intuitive, integrated staining, workflow management platforms, and digital pathology solutions optimize laboratory efficiencies to reduce errors, support diagnosis and inform treatment decisions for anatomic pathology professionals. Together with Roche, VMSI is driving Personalized Healthcare through accelerated drug discovery and the development of "companion diagnostics" to identify the patients most likely to respond favorably to specific therapies.  VENTANA and the VENTANA logo are trademarks of Roche. Visit http://ventana.com/ to learn more.

VMSI Media Relations
Jacqueline Bucher
Senior Director, Corporate Communications
Phone: 520-877-7288
e-mail: jacquie.bucher@ventana.roche.com

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates in 50 countries and more than 46,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine. In 2012, Boehringer Ingelheim achieved net sales of about €14.2 billion. R&D expenditure in the business area Prescription Medicines corresponds to 22.5% of its net sales.

For more information, go to www.boehringer-ingelheim.com.

Media Contact
Dr. Reinhard Malin
Boehringer Ingelheim GmbH
Launch Products Core
Phone: +49 (6132) 77-90815
Email: reinhard.malin@boehringer-ingelheim.com

US Media Contact
Susan Holz
Public Relations
Phone: 203-798-4265
Email: susan.holz@boehringer-ingelheim.com


'/>"/>
SOURCE Ventana Medical Systems, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Life Technologies to Collaborate with Merck Serono for Companion Diagnostics Development and Commercialization
2. QB3 to Collaborate with Johnson & Johnson Innovation on New Incubator
3. Freeslate Collaborates with Medicines for Malaria Venture to Advance Therapeutic for Treating Malaria
4. DuPont Tate & Lyle Bio Products Collaborates with RML Incorporated to Develop Bio-Based Solution for Personal Care Products
5. Research Foundations Collaborate To Fund Phase 1 Study Of Cancer Drug In Alzheimers Disease Patients
6. Sigma Life Science and the Culture Collections of Public Health England Collaborate to Distribute Cells and Cellular Extracts
7. DuPont Collaborates with Agricultural Educators to Reach More Students
8. DuPont Pioneer and Mendel Biotechnology, Inc. Collaborate to Improve Water Use Efficiency and Photosynthesis in Corn
9. Lockheed Martin and Nanyang Technological University to collaborate on nanotechnology
10. Elsevier and Kanazawa University in Japan Collaborate to Map Universitys Research Performance
11. Ceres and Syngenta to Collaborate on Sweet Sorghum Market Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... ... Biologist Dawn Maslar MS has found a biomarker that she claims verifies ... The Neuroscience of Meeting, Dating, Losing Your Mind, and Finding True Love, Maslar found ... step, in my estimation, was to scientifically track the evidence of commitment in men,” ...
(Date:6/20/2017)... ... June 20, 2017 , ... GigaGen Inc ... millions-diverse immune repertoires, announces launch of its new Surge(TM) Discovery service ... CEO of GigaGen, will present on Surge at the conference. , Surge is ...
(Date:6/16/2017)... ... June 16, 2017 , ... ... commercialization, has just announced two more sessions of its “From the Helm” Webinar ... on the world of online templates for design control exercises. Led by David ...
(Date:6/15/2017)... , ... June 15, 2017 , ... ... Gallery (EKG) follows an artist’s journey through creative experimentation and interdisciplinary collaboration. Feature ... runs through July 22nd. An opening reception will be held at EKG, located ...
Breaking Biology Technology:
(Date:6/14/2017)... 15, 2017  IBM (NYSE: IBM ) is introducing several ... dedicated to developing collaboration between startups and global businesses, taking ... During the event, nine startups will showcase the solutions they ... industries. France is ... with a 30 percent increase in the number of startups ...
(Date:4/24/2017)... WASHINGTON , April 24, 2017 ... counsel and partner with  Identity Strategy Partners, LLP ... "With or without President Trump,s March 6, ... Foreign Terrorist Entry , refugee vetting can be instilled ... refugee resettlement. (Right now, all refugee applications are ...
(Date:4/13/2017)... According to a new market research report "Consumer ... Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - ... to grow from USD 14.30 Billion in 2017 to USD 31.75 Billion ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):